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Abstract
Background: Cervical cancer is the second commonly diagnosed cancer and the second leading cause of cancer
death in women in Ethiopia, with rates among the highest worldwide. However, there are limited data on cervical
cancer treatment patterns and survival in the country. Herein, we examine treatment patterns and survival of
cervical cancer patients treated in Tikur Anbessa Hospital Radiotherapy Center (TAHRC), the only hospital with
radiotherapy facility in the country.
Methods: Women with histologically verified cervical cancer who were seen in 2014 (January 1, 2014 to December
31, 2014) at TAHRC were included. Information about clinical characteristics and treatments were extracted from the
patients’ medical record files. The information on vital status was obtained from medical chart and through
telephone calls.
Result: Among 242 patients included in the study, the median age at diagnosis was 48 years. The median waiting
time for radiotherapy was 5.6 months (range 2 to 9 months). Stage migration occurred in 13% of patients while
waiting for radiotherapy. Consequently, the proportion of patients with stage III or IV disease increased from 66% at
first consultation to 74% at the initiation of radiotherapy. Among 151 patients treated with curative intent, only 34
(22.5%) of the patients received concurrent chemotherapy while the reaming patients received radiotherapy alone.
The 5-year overall survival rate was 28.4% (20.5% in the worst-case scenario). As expected, survival was lower in
patients with advanced stage at initiation of radiotherapy and in those treated as palliative care.
Conclusion: The survival of cervical cancer patients remains low in Ethiopia because of late presentation and delay
in receipt of radiotherapy, leading to stage migration in substantial proportion of the cases. Concerted and
coordinated multisectoral efforts are needed to promote early presentation of cervical cancer and to shorten the
unacceptable, long waiting time for radiotherapy.
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Background
Cervical cancer is the fourth most common type of cancer
among women worldwide [1, 2]. Of the 500,000 cervical
cancer cases and 270,000 deaths estimated to occur world-
wide each year, 85% of them occur in LMICs, which are
least equipped to screen and treat these patients because of
poor healthcare infrastructure [2, 3]. The burden is highest
in Eastern Africa, with estimated age-standardized inci-
dence rates of > 30 per 100,000 women [3, 4]. In this region
cervical cancer remains a leading cause of cancer death in
women, accounting for one in five of all cancer deaths [5].
Ethiopia with the population of more than 110 million,
is among countries with the highest incidence rate of
cervical cancer worldwide, with about 6000 new cases
diagnosed each year [6, 7]. Cervical cancer is the second
most commonly diagnosed and the second leading cause
of cancer death in the country, with age standardized in-
cidence and mortality rate of 26.4 and 18.4 per 100,000
population each year, respectively (GLOBOCAN 2012)
[8]. One of the major challenge of cervical cancer care is
Ethiopia is delay in diagnosis, since most of the patients
seek medical care at advanced stage of the disease [7, 9].
Tikur Anbessa Specialized Hospital is the only oncology
center for the radiotherapy treatment, which is the
major treatment modality for locally advanced and ad-
vanced cervical cancer; all patients are referred to this
hospital from all over the country [9, 10]. However, the
number of cervical patients is continuously increasing
from year to year, which makes the waiting time for re-
ceipt of radiation treatment to be very long [7, 9, 10].
Therefore, delays in treatment is another major chal-
lenge of cervical cancer care in Ethiopia.
Methods
Study setting and treatment modality
The study was carried out in adult oncology department
of Tikur Anbesa Specialized Hospital (TASH) radiother-
apy center, under the Addis Ababa University. During
the study period in 2014 (January 1, 2014 to December
31, 2014), there were three clinical oncologists, six resi-
dents, one General practitioner, and one palliative care
physician serving the center. The center had two cobalt-
60 radiotherapy machines. The center had no brachy-
therapy machine during the study period.
Patients with cervical cancer were referred from all
over Ethiopia to Tikur Anbessa Hospital Radiotherapy
center for radiotherapy. Up on first oncologist consult-
ation and/or radiotherapy planning, tumor stage were
classified according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system [11].
The stage was based mainly on clinical pelvic examin-
ation by at least one clinical oncologist from radiother-
apy center. The routine radiological examination such as
chest X-ray and abdomino-pelvic ultrasound
examination will aid to classify the FIGO stage further-
more, in case of hydronephrosis or metastatic lesion was
detected.
According to the treatment protocol of the center, cer-
vical cancer patients FIGO stage IIA and lower were
treated surgically with radical hysterectomy and pelvic
lymphadenectomy (Wertheim). Patients with FIGO stage
IIB and above without surgery or patients who under-
gone surgery but has positive surgical margins and posi-
tive lymph nodes required radiotherapy. Patients with
early stage disease but unable to undergo surgery due to
other medical conditions also treated with radiotherapy.
The radiotherapy planning techniques were two-
dimensional (2D-technique). Generally, patients with
early stage IIIB and/or stage less than early IIIB with
good general condition were treated with curative dose
radiotherapy in two phases. However, for patients with
FIGO stage above late stage IIIB and/or for patients in
emergency state palliative radiotherapy is usually offered.
The radiation dose and fractionation depend on the in-
tent of treatment, with curative intent cases treated with
conventional RT with radiation dose of 66–72 Gys in
two phases while palliative intent cases treated with
hypofractionation with varied radiation doses which
could be 10 Gys single fraction, 20 Gys in 5 fractions, 30
Gys in 10 fractions based on disease stage and general
health status of the patient (e.g., state of renal failure or
uremia and presence or absence of Fistula).
Study design and statistical analysis
Women with histologically verified Cervical cancer
(International Classification of Disease-Oncology (ICD-
O-3) codes C53.0–9) who were treated in 2014 at the
Radiotherapy Center at Tikur Anbessa Hospital Addis
Ababa, Ethiopia, were included in the study,
retrospectively.
Information on demographic and tumor characteris-
tics, treatments, and response to treatment at 1 year was
extracted from the patients’ medical record files. The
date of diagnosis was assigned as the date of referral
with the suspicion of cervical cancer or the date of bi-
opsy confirmation, whichever is first. Information on
vital status was obtained from medical records or the pa-
tients or –in case of death- from the relatives through
telephone calls. If patients or relatives were not reached
by telephone, the last date of personal contact in Tikur
Anbessa hospital was taken from the patients’ files. For
these patients the additional worst-case scenario analysis
was performed with assumption of dead after 6 months
of last follow-up date registered on their medical record
[12] . The telephone calls were made between 01/02/
2018 to 30/03/2018.
The primary end point of this study was overall sur-
vival. Groups are compared using parametric (t test) and
Deressa et al. BMC Cancer         (2021) 21:1102 Page 2 of 7
nonparametric (Chi-square, Mann-Whitney U test) tests.
Kaplan-Meier curve and survival analysis was performed
using Log-rank test to assess significant differences be-
tween groups regarding survival. All p values less than
0.05 were considered significant. All data were analyzed
using SPSS 20.0 (IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY: IBM
Corp.) and R 3.4.2. (R Core Team (2017). R: A language
and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. URL https://
www.R-project.org/.)
The ethical clearance was obtained from the Ethical
review committee of the Radiotherapy unit of Tikur
Anbessa Hospital under Addis Ababa University College
of Health Sciences (AAU CHS). Informed consent was
waived by the same ethics committee that approved the
study, considering the study was mainly based on the
retrospective record analysis.
Result
Characteristics of the patients and their treatment
Three hundred forty-nine cervical cancer patients re-
ceived radiotherapy in Black Lion Hospital in 2014. Of
those, 242 patient files could be retrieved. The median
age at diagnosis was 48 years (range 27 to 86). The aver-
age number of births they gave was 5.62 (±2.88). HIV
was relatively the commonest comorbidity, in which 26
(11%) were found to be positive (Table 1).
Most of the patients had no surgery for cervical cancer
prior to their presentation to radiotherapy center; only
26 (11%) patients underwent surgery. The median wait-
ing time for radiotherapy was 5.6 months (range 2 to 9
months). During the waiting time, 31 (13%) patients
showed stage migration from their baseline at the first
oncologist consultation. There was a difference in wait-
ing time for initiation of RT based on the stage and in-
tent of treatment. About 55 patients (60.4%) s treated
with palliative intent received RT within 3months after
diagnosis, while only 31 patients (20.5%) received RT
within 3 months in curative intent groups (p < 0.001).
The waiting time for receipt of RT also differed by stage.
The number of patients who received RT with 3months
were 13 (15.1%), 38 (44.2%) and 35 (40.7%) for stage I/II,
III and IV, respectively (p < 0.001).
Thirty-four (14%) patients received concurrent chemo-
therapy with radiation while the remaining (majority of)
patients received radiation therapy alone. Most of the
patients were had lost from follow-up in Tikur Anbessa
hospital before 1 year (Table 1).
Survival
Among 242 patients included in the study, 140 (57.9%)
were known dead while 102 (42.1%) patients were alive
or censored. For worst-care scenario we estimated that
patients had died 6 months after their last follow up if
they were not responding on telephone calls. This results
in 184 (76%) deceased, while 58 (24%) were known alive
within 6 months before the study closure date.
The estimated 60 months (5 year) overall survival
probabilities were 28.4% (SE 4.0) in the main analysis.
The one-year, two-year, three-year and four-year overall
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aAmong 82 patients with stage I/II, 75 (91%) patients was FIGO stage IIB, 5
(6%) was stage IIA and 2 (3%) was stage IB
bAmong 64 patients with stage I/II, 61 (95%) patients was FIGO stage IIB, 2
(3%) were stage IB and 1 (2%) was stage IIA
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survival probabilities were 77% (SE 2.8), 45.3% (3.5),
36.0% (SE 3.4) and 32.2% (SE 3.5), respectively. The me-
dian overall survival time was 23.0 months (95% CI
18.5–27.5).
However, in the worst-case scenario the 60 months (5
year) overall survival probability reduced to 20.5% (SE
3.2) and the median overall survival to 18 months (95%
CI 15.6–20.3). The one-year, two-year, three-year and
four-year overall survival probabilities were 74.3% (SE
2.8), 35.2% (SE 3.1), 27.2% (SE 2.9) and 24.4% (SE 2.9),
respectively.
FIGO stage has significant impact on survival of pa-
tients. The median of stage I/II is not reached due to
survival percentage in this group, 53.7% is above 50%
needed for median. Therefore, median survival for stage
I/II group is below 53.7% and mean survival is 42.0 (95%
CI 38.2–47.6) months. The estimated median time of
survival based on the stage at the initiation of radiother-
apy was, 19.0 (95% CI 13.4–24.6) and 14.0 (95% CI 9.2–
18.8) months for stage III and IV, respectively (p <
0.001) in main analysis (Fig. 1).
In the worst-case scenario, the median survival in I/II
is reached, but only one patient died and the survival
percentage is 49.2% (SE 7.6%). The median survival for
stage I/II groups is 52 months, but no confidence
interval can be calculated. The mean survival for this
group is 40.7 (95% CI 35.9–45.4%) months. The esti-
mated median time of survival based on the stage at the
initiation of radiotherapy declined to 17.0 (95% CI 14.7–
19.3) and 12.0 (95% CI 9.2–14.7) months for stage III
and IV, respectively (p < 0.001) in main analysis (Fig. 1).
As expected, patients treated with curative intent had
significantly better survival as compared to those treated
with palliative intent. The median survival was 44.0 (95%
CI 31.0–56.9) and 13.0 (95% CI 11.2–16.7) months for
patients treated with curative and palliative intent, re-
spectively in main analysis group (p < 0.001). In the
worst-case scenario the median survival time was 28.0
(95% CI 20.9–35.0) and 12.0 (95% CI 10.3–13.7) months
for patients treated as curative and palliative intent, re-
spectively (p < 0.001) (Fig. 2).
Discussion
To our knowledge, this study is the first study to report
on the 5-year survival of cervical cancer patients in
Ethiopia. The 1-year and 2-year overall survival rates in
our study (77 and 45.3%) were substantially lower than
those reported in previous studies in TAHRC. Kantel-
hardt et al. reported a one-year and two-year survival
rates of 90 and 74% (45% in the worst-cases analysis),
Fig. 1 Overall survival of patients according to the stage during receipt of radiotherapy: A Kaplan-Meier analysis with original data, and B The
worst-case scenario Kaplan-Meier analysis
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respectively [12]. Similarly, Moelle and colleagues et al.
documented a one-year and two- year survival of 84%
(54% in the worst case) and 64% (35% in the worst case),
respectively, based on patients treated between 2008 to
2013 [13]. While the clinical characteristics and treat-
ment patterns of patients between our study and those
previous studies are generally similar, waiting time for
initiation of radiotherapy after first consultation with on-
cologist was substantially longer in our study (5.8
months vs. 3.8 months) [12]. This may in part have con-
tributed to the lower survival rates in our study due to
greater disease progression and stage migration. Since
our study was conducted 2018 compared to the other
two studies in 2013, there were more patients actively
using a mobile phones and thus better information on
the endpoint (death) could be obtained. Since survival
probabilities of our study are within the range of the
worst-case analysis of the other two studies, we assume
to have ascertained more deaths in our main analysis
leading to the lower survival probability in the main
analysis.
In general, our survival findings are 15–25% lower
than those reported in high income countries such as
the United States and in some countries in Africa [14] in
part because of lack of standard of care such as
brachytherapy, known to improve cervical cancer sur-
vival [15, 16]. In a single institution experience from
Ghana, patients treated with Coblt-60 machine and then
with brachytherapy boost has 86% of 3-year overall sur-
vival, [17] which is much higher than our findings in pa-
tients treated with curative intent radiotherapy which is
50%. In contrast, stage-specific cervical cancer survival
rates in Kenya where patients are treated only with
Cobalt-60 machine, reported median survival of 18, 15
and 11 months for Stage II, III and IV patients, respect-
ively [5]; and in our cases 40.7, 17 and 12 months for
stage I/II, stage III and stage IV patients, respectively.
Here, the median survival for stage II patients were
higher in our case, but the median survival of stage III
and IV is comparable. However, brachytherapy service in
TAHRC has been available to cervical cancer patients
since 2015. It will be of interest to assess whether sur-
vival of cervical cancer patients has improved in the hos-
pital following the availability of this life-saving therapy.
Concomitant chemo-radiotherapy for locally advanced
cancer patients has become standard of care since the
late 1990s, after several study documented the survival
benefit of this therapy compared to radiotherapy alone
[18–20]. The treatment protocol of cervical cancer in
Tikur Anbessa hospital radiotherapy center also
Fig. 2 Overall survival of patients according to the intent of radiotherapy: A Kaplan-Meier anaysis with original data, and B The worst-case
scenario Kaplan-Meier analysis
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recommends concurrent chemo radiotherapy especially
in curative setting [12]. However, only 14% of the pa-
tients in our cohort received combined treatment, and
these patients had a better survival than those who re-
ceived radiotherapy alone. Barriers to receipt of concur-
rent chemotherapy are likely thought to be financial
hardship, high patient load, lack of space and lack of co-
ordination [13].
In addition to sub-standard treatments, the low sur-
vival rate of cervical cancer patients in our study in part
reflects late stage presentation, as is the case in many
sub-Saharan African countries [5, 21, 22]. The majority
of our patients had stage III or IV disease at the time of
first oncologist consultation, which is consistent with
previous studies in the country [12, 13]. Most of these
patients received palliative radiotherapy, [23] and in
shorter waiting time than patients with early-stage dis-
ease. However, this may have compromised the survival
of patients with early-stage disease, who may benefit
more from timely treatment. While expansion of radio-
therapy services (number of radiotherapy machines and
personnel) is likely to take many years for optimal solu-
tion, some novel strategy is needed in the short term for
timely treating of patients with early-stage disease, who
may benefit more from timely radiotherapy.
A strength of our study is it showed long-term survival
probability of cervical cancer and the predictors for sur-
vival in Ethiopia. It also showed the impact of longer
waiting time on the overall treatment outcome. It can
also help as the reference for the assessment of success
in various actions taken to improve access to care. Limi-
tations of our study include missing information (med-
ical records) for many patients and lack of regular follow
up after radiotherapy. Our findings of survival rates may
be affected by loss to follow-up or ascertainment bias.
We did not also have data on radiotherapy dose and
schedules, adherence to treatments, general health per-
formance, and nutritional status, which all influence
survival.
Conclusion
The survival of cervical cancer patients in Ethiopia
(treated in TAHRC) remains low because of late stage
presentation, suboptimal treatments (lack of brachyther-
apy), and disease progression while waiting for radio-
therapy. These findings underscore the need for
concerted, multisectoral efforts to improve early detec-
tion access to timely and high-quality radiotherapy
services.
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